Table 1.

Demographic and HSCT data of study participants

Characteristic	Number (n = 80)
Median age (range), y	9.4 (0.5-37.9)
Female	28
Underlying diagnosis
Malignancy	32
Primary immune deficiency	17
Hemoglobinopathy	4
Metabolic disorder	4
Bone marrow failure	22
Platelet function disorder	1
Conditioning regimen
Myeloablative	57
Reduced intensity	23
HLA match
5/10	3
6/10	2
7/10	1
8/10	5
9/10	13
10/10	56
Donor relation
Related	18
Unrelated	62
Stem cell source
Bone marrow	42
Peripheral blood stem cells	33
Umbilical cord blood	5
Acute GVHD prophylaxis
CNI + MMF	20
CNI + MMF + abatacept	27
T-cell depletion∗	25
CNI + methotrexate + abatacept	2
CNI + MMF + posttransplant cyclophosphamide	2
CNI + methylprednisolone	3
Sirolimus + abatacept	1
Clinical outcomes
Acute GVHD	16
Skin GVHD	13
GI GVHD	6
BSI by day +30	21
Mucosal barrier injury–related BSI by day +30	14
Moderate/high-risk TA-TMA	32

CNI, calcineurin inhibitor; MMF, mycophenolate mofetil.

^∗In vitro T-cell depletion included either CD34⁺ selection or T -cell receptor alpha/beta/CD19⁺ depletion.